Produktname:6-Bromo-3,4-dichloroquinoline
IUPAC Name:6-bromo-3,4-dichloroquinoline
- CAS：927801-17-0
- Molekulare Formel：C9H4BrCl2N
- Reinheit：97%
- Katalognummer：CM260590
- Molekulargewicht：276.94
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:927801-17-0
- Molekulare Formel:C9H4BrCl2N
- Schmelzpunkt:-
- SMILES-Code:ClC1=C(Cl)C=NC2=CC=C(Br)C=C12
- Dichte:
- Katalognummer:CM260590
- Molekulargewicht:276.94
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Quinolines
- Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
- Quinoline Price
- if you have any question on quinoline price, we will give the professional answers to your short questions.
Column Infos
- Paltusotine
- Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease.
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.
Suche 
+86 21 5895 0110 
